Publications
CAR T Cells
G-Rex®100M, G-Rex®24 Well Plate, G-Rex®6 Well Plate
Publication Date: July 25, 2025
HER2-targeted Tmod cells, which pair a trastuzumab-derived CAR activator with an HLA-A*02 LIR-1 blocker, killed HLA-A*02-negative tumor cells while sparing otherwise identical HLA-A*02-positive cells. In primary T cells from five donors the CAR was about twice as potent as Tmod and 3.5 times as potent as Tmod(sh), yet both gated constructs achieved roughly 20-fold selectivity. Selectivity held in three-dimensional A375 and H508 spheroid co-cultures, including spheroids with added HLA-A*02-positive fibroblasts, and in dual-flank xenografts given 2E7 T cells, where Tmod cleared tumor grafts but left the "normal" grafts intact. Without antigen, receptor-positive Tmod(sh) cells drifted from 9…
Publications
TIL Cells
G-Rex®100M, G-Rex®10M
Publication Date: July 6, 2025
A streamlined TIL manufacturing process for non-small cell lung cancer cut culture time and reagent costs while yielding TILs with stronger killing of matched tumor cells than a published Moffitt Cancer Center protocol. Fragments were expanded in G-Rex® flasks with T-cell-specific medium, human platelet lysate, reduced GMP-grade IL-2 and CD3/CD28 nanobeads instead of feeder cells. TILs grew from all 35 tumor samples in preREP and all 16 tested in REP, averaging 200 billion cells after a 2-week REP, predominantly memory phenotype. In three matched organoid pairs, nanobead-activated TILs killed 15% to 54% of tumor cells across 1:1 to 20:1 ratios versus 9% to 30% for the Moffitt method, alth…
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: June 28, 2025
Allogeneic CD19 CAR T cells that combine hypoimmune editing (HLA class I and II depletion with CD47 overexpression) with FKBP12 knockout stayed active in the presence of tacrolimus and rapamycin and controlled Nalm6 leukemia in immunosuppressed humanized mice. In vitro, FKBP12-knockout cells killed B cells and Nalm6 cells at high drug concentrations, while unedited CAR T cells failed. Hypoimmune cells also avoided allogeneic T-cell, NK-cell and macrophage responses. Mice received 350,000 CAR T cells three days after 50,000 Nalm6 cells. Over 25 days, only hypoimmune FKBP12-knockout cells prevented tumor expansion in all 5 mice, engrafted in spleen and bone marrow, and depleted bone marrow…
Publications
TIL Cells
G-Rex®100M, G-Rex®24 Well Plate
Publication Date: June 21, 2025
Autologous tumor-infiltrating lymphocytes selected for mutation reactivity and edited by CRISPR/Cas9 to knock out the checkpoint protein CISH were successfully manufactured under cGMP for patients with metastatic gastrointestinal cancers. Tumor fragments were grown in 24-well G-Rex® plates for six weeks, screened for neoantigen reactivity, stimulated, electroporated with Cas9 mRNA and guide RNA, and expanded for 14 days with irradiated feeder cells in 100 cm2 G-Rex® vessels holding 600 mL. Nineteen of 22 tumor samples, from 20 patients, proceeded to editing and expansion, and 13 patients received TIL. Final products had mean viability of 76%, mean CD3 of 94.4%, and mean viable TIL fold ex…
Publications
CAR T Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: June 12, 2025
BMS-986408, a dual inhibitor of the lipid kinases DGKα and DGKζ, strengthened both PD-1 checkpoint therapy and CD19 CAR T-cell therapy in preclinical models. It inhibited recombinant DGKα and DGKζ with IC50 values of 0.0003 and 0.002 μM. Combined with anti-PD-1, it produced 90-100% complete tumor regression in SA1N, MC38 and CT26 tumors, versus 40%, 10% and 0% with anti-PD-1 alone. Inhibiting both enzymes was needed to maximize this benefit. In NSCLC patient-derived tumor spheroids, the combination with nivolumab raised IFNγ significantly in 6 of 10 samples. In mice, co-dosing with wild-type CD19 CAR T cells matched the tumor control and expansion of dual DGKA/DGKZ knockout CAR T cells in…
Publications
CAR T Cells
Publication Date: June 12, 2025
A CSF1R-positive, CD14- and CD68-positive myeloid-monocytic population, termed LAMM cells, was found in aggressive B cell lymphoma and linked to poor response to anti-CD19 CAR-T therapy. In 106 patients treated in Cologne, a LAMM gene signature, high in non-durable responders, was associated with worse outcome, and LAMM cells were associated with lower T cell infiltration. Ex vivo, LAMM cells generated from monocytes suppressed CAR-T expansion and cytotoxicity; cell-cell inference implicated PGE2 signaling via EP2/EP4, and CAR-T cells lacking both receptors showed improved tumor killing and higher expansion. In high-tumor-volume PPMBC lymphoma mice, anti-CSF1R antibody plus 2 × 10^6 CAR-T…
Publications
VST Cells
G-Rex®24 Well Plate
Publication Date: June 11, 2025
People with primary sclerosing cholangitis (PSC) show expanded T and B cell responses against Epstein–Barr virus (EBV). Sequencing the T cell receptor repertoires of 504 people with PSC and 904 healthy controls identified 1,008 PSC-associated clonotypes, most restricted to known HLA risk alleles such as HLA-B*08:01 and HLA-DRB1*03:01, and EBV-specific clonotypes were the only pathogen group enriched. Phage-immunoprecipitation sequencing of sera from 120 patients and 202 controls showed a higher share of anti-EBV antibody responses, including against the lytic protein BMRF1. EBV-specific T cell lines from four patients, cultured in a 24-well G-Rex® device, recognized autologous lymphoblast…
Publications
Treg Cells
Publication Date: June 4, 2025
A manufacturing process for SRC-3 knockout human regulatory T cells was developed using CRISPR-Cas9 ribonucleoprotein nucleofection of CD4+CD25+ cells isolated from donor blood. Of two guide RNAs targeting NCOA3, sgRNA4 edited more efficiently, but sgRNA3 was chosen because GUIDEseq showed about 96 % on-target reads versus about 55 %. Among four protocol orders, nucleofection immediately after isolation followed by four days of TCR stimulation (protocol 2) was selected for simplicity and the purest Treg population. In G-Rex® devices the edited cells expanded 25–40-fold over 14 days, three to five-fold more than in standard dishes. Cryopreserved cells kept viability, but FOXP3 expression f…
Publications
Treg Cells
G-Rex®10
Publication Date: June 3, 2025
A GMP protocol expanded regulatory T cells from paediatric thymus tissue (Thy-Tregs) into cryopreserved clinical doses intended for children undergoing heart transplantation. Enzyme-free mechanical dissociation, CD8 depletion and CD25 enrichment yielded a mean of 4.54 × 10^6 Tregs per gram of tissue. CTS Dynabeads Treg Xpander outperformed TransAct in expansion, suppressive function and CD25/FOXP3 co-expression. In a G-Rex® bioreactor, restimulation at day 10 instead of day 7 gave nearly 2.4 times higher fold expansion. Two laboratory-scale validation runs and one full-scale GMP engineering run, cultured with IL-2 and rapamycin, exceeded 200-fold expansion by day 23 (range 230–3127), with…
Publications
CAR T Cells
G-Rex®100, G-Rex®100M
Publication Date: June 2, 2025
A semi-automated, software-controlled workflow linking DynaCellect, Rotea and Xenon instruments produced functional non-viral CD19 CAR T cells from healthy-donor leukopaks. T cells were isolated with Dynabeads, activated for 2 days in a G-Rex® bioreactor, debeaded, electroporated with a CRISPR/Cas9 TRAC knock-in payload, expanded 7 days and harvested on day 9. Across three donors, about 850 million viable cells were recovered on day 2, 24% to 35% of cells were edited, fold expansion was 7, 14 and 10, and residual beads stayed below 100 per 3 million cells. Edited cells killed NALM6 targets more effectively than non-electroporated controls.
Publications
NK Cells
G-Rex®100M, G-Rex®100M-CS, G-Rex®10M, G-Rex®10M-CS
Publication Date: May 26, 2025
Umbilical cord blood CD34+ progenitor-derived NK cells (RNK001) were produced under GMP in G-rex bioreactors and cryopreserved into an off-the-shelf product that kept anti-tumor function after infusion in mice. Cells were expanded in a G-rex 10M for nine days, then a G-rex 100M, with six medium additions, reaching a mean 767-fold expansion and 1.4–2.4 × 10^9 CD56+CD3- cells in the validation runs. After controlled-rate freezing in CryoStor CS10, mean post-thaw viability was 67% and recovery 75%. Thawed cells lysed SKOV-3 spheroids in 3D collagen comparably to fresh cells. In NXG mice, thawed cells persisted similarly to fresh cells after intraperitoneal or intravenous infusion and showed…
Publications
NK Cells
G-Rex®6 Well Plate
Publication Date: May 22, 2025
Activating primary human NK cells with PMA and ionomycin instead of irradiated K562 feeder cells produced anti-CD19 CAR-NK cells of comparable quality. In small-scale T-75 flask cultures, viability, expansion, CD25 and PD-1 were similar, but CAR expression was lower with the feeder cell-free method. When transduced cells were expanded for 14 days in a G-Rex® 6-well plate, CAR expression, viability and expansion did not differ between methods. Feeder cell-free CAR-NK cells showed higher Nalm6 killing at a 5:1 effector-to-target ratio and higher IFN-gamma release, and they triggered less IL-6 and IL-1 beta secretion from THP-1 myeloid cells. Adding the Src inhibitor PP2 did not improve CAR-…
No manuscripts match your filters.